Share This

Hot News

據報內地考慮引進復必泰疫苗 @ 2022-04-27T08: Back Hot News
Keyword:疫苗 中國
Concept:復必泰疫苗 , 內地考慮引
德國《明鏡周刊》報道,隨著上海等多地新型冠狀病毒疫情擴大,中國考慮引入輝瑞(PFE.US)及BioNTech(BNTX.US)生產的 復必泰疫苗,改變原本只使用國產 ...
據報中國因應疫情擴大,計劃引入輝瑞及BioNTech生產的 復必泰疫苗。復星醫藥(2196)今早高開5.6%,報33元。德國《明鏡周刊》報道,隨著上海等地新.
據報中國因應疫情擴大,計劃引入輝瑞及BioNTech生產的 復必泰疫苗。復星醫藥(2196)今早高開5.6%,報33元。至上午10時45分,報32.1元,仍升2.72%。
【Now新聞台】德國《明鏡周刊》報道,隨著上海等地疫情擴大,內地考慮引進德國BioNTech生產的疫苗。 前年爆發新冠病毒疫情後,德國藥廠BioNTech與美國 ...
德國《明鏡周刊》(Der Spiegel)報道,隨著上海等地疫情擴大,中國改變原先只用國產疫苗的立場,考慮引進德國BioNTech生產的BNT疫苗。
德國《明鏡周刊》報道,隨著上海等地新冠疫情擴大,中國改變立場,考慮引入輝瑞及BioNTech生產的復必泰疫苗。 報道指,由於中國的 科興疫苗一直未獲歐盟認可,令復必泰 ...
復星醫藥(02196)逆市上升,H股高見33元,升5.6%,現報31.7元,升1.28%。據本港傳媒引述德國《明鏡周刊》指,隨著上海等地新冠疫情擴大, ...
德國明鏡周刊報導,隨著上海等地疫情擴大,中國改變原先只用國產疫苗的立場,考慮引進德國BioNTech生產的BNT疫苗。
Omicron變異株似乎揭露出陸制疫苗保護力較低的問題,科學家大聲疾呼,吁請北京當局開放外國疫苗,如此一來才能終結本波疫情,避免封城傷害經濟。
德國《明鏡周刊》(Der Spiegel)日前指,隨著中國上海疫情擴大,北京此前只用國產疫苗的立場改變,考慮引進德國生物新技術公司(BioNTech)與 美國藥 ...

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.